DiscoverThe Heidrick & Struggles Leadership PodcastCarsten Brunn on moving from big pharma to biotech: Risk, rewards, and leadership styles
Carsten Brunn on moving from big pharma to biotech: Risk, rewards, and leadership styles

Carsten Brunn on moving from big pharma to biotech: Risk, rewards, and leadership styles

Update: 2023-07-26
Share

Description

In this next episode of The Heidrick & Struggles Leadership Podcast, Heidrick & Struggles’ Charlie Moore speaks to Carsten Brunn, the president and CEO of Selecta Biosciences, a clinical-stage biotech company with a commitment to solving the challenges associated with autoimmunityheadquartered in Boston, Massachusetts. Brunn, who moved into biotech from Bayer, discusses the differences—cultural, day-to-day, and leadership capabilities needed—between biotech and big pharma. He shares what surprised him, the challenges he faced when he first joined Selecta Biosciences, and managing his relationship with the board of directors. Finally, he offers advice to leaders considering a move into the biotech space.

Hosted on Acast. See acast.com/privacy for more information.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Carsten Brunn on moving from big pharma to biotech: Risk, rewards, and leadership styles

Carsten Brunn on moving from big pharma to biotech: Risk, rewards, and leadership styles